Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Balloons vs. Puddles: Can We Do Smaller Surgeries after Induction Therapy for NSCLC?
Author
Howard (Jack) West, MD

In my thoracic oncology tumor board today, we discussed a situation that comes up fairly often: a patient has a collapsed lung lobe from a tumor near the middle of the chest, with some regional lymph nodes involved, and the surgeon thinks he's likely to need the whole lung removed because the location of the tumor is nestled in just the wrong place.  The patient has enough lung function to undergo surgery, but losing an entire lung (pneumonectomy) is a big loss, and he's already only a debatable candidate to be able to undergo surgery safely.  So the question emerges, "Can we give pre-operative chemotherapy specifically with the intent of shrinking a cancer enough to enable a less extensive surgery than would be needed if no pre-operative therapy is done?"

It's a question that doesn't have a clear answer.  The concept of "downstaging" a cancer with neoadjuvant (pre-operative) chemotherapy or chemo/radiation is an appealing potential appeal of the strategy, but there isn't clear evidence that it really works.  In the ChEST trial that has been recently published that compared pre-operative cisplatin/gemcitabine chemotherapy followed by surgery to surgery alone, the recipients of neoadjuvant therapy were less likely to have undergone a pneumonectomy (17% vs. 25%) and more likely to have received a lobectomy (70% vs. 60%) .  On the other hand, the SouthWest Oncology Group (SWOG) ran a similar neoadjuvant chemotherapy trial and found that there were no differences in the pneumonectomy rates with or without pre-op chemo -- 17% in both arms.  What gives?

Part of the challenge is that surgeons have different styles: some have come to believe that a cancer is like a balloon, and if it appears to shrink, you presume that the new borders of the cancer don't have any additional cancer around them.  Therefore, it's OK to do a smaller surgery than you would have originally done.  On the other hand, some surgeons see a cancer as a puddle drying up, so that even though the main borders are smaller on repeat scans, and maybe even when directly visualized by the surgeon, you can't be confident that there aren't little satellite areas of cancer outside of the main borders.  Therefore, they feel that if someone needed a pneumonectomy originally, you can't do a smaller surgery after pre-operative therapy, even if it looks as if the cancer is now small enough to enable a more limited surgery.

So the question of which patients receive a larger or smaller surgery depend only in part on what their tumor requires, and in part on the philosophy of the medical team (but usually especially the surgeon, who tends to get more votes in such matters).   We can't rely on the rates of pneumonectomy vs. lobectomy to tell us whether all of the pneumonectomies were clearly needed or not.  What would be most helpful would be to determine if the patients who were deemed to require a pneumonectomy that was then converted to a lobectomy do just as well as the patients who were anticipated to require a lobectomy from the beginning.  But to my knowledge, we don't have any such data.

In the end, let me give you a sense of how variable these styles are. I work with four board-certfied, excellent thoracic surgeons who get along amazingly well, even if they don't all do things the same way. Two of them favor revising the surgery after pre-operative therapy, and two favor doing the original surgery that would have been required.  And the one who presented the case today? He favored pre-operative therapy for a patient we shared a few months ago (but who ended up requiring a pneumonectomy after neoadjuvant chemo/radiation anyway), but for this particular patient, he favored up front surgery with a pneumonectomy.  In the more recent case, he wasn't at all optimistic that the operative options would be better after chemo or chemo/radiation.  It just goes to show how individualized patients and their cancers can be, with no "right way" for everyone, even with the same surgeon and team.

Next Previous link

Previous PostNext Post

Related Content

Image
Trial data ASCO 2024
Video
In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO. To watch the complete playlist, click here.         
Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Image
Case Based Panel
Video
The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.

Forum Discussions

Hi elysianfields and welcome to Grace.  I'm sorry to hear about your father's progression. 

 

Unfortunately, lepto remains a difficult area to treat.  Recently FDA approved the combo Lazertinib and Amivantamab...

Hello Janine, thank you for your reply.

Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...

Hi elysianfields,

 

That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...

Recent Comments

JOIN THE CONVERSATION
I could not find any info on…
By JanineT GRACE … on
Hi elysianfields,

 

That's…
By JanineT GRACE … on
Hello Janine, thank you for…
By elysianfields on
EGFR
By happybluesun on